ALLMedicine™ Anklyosing Spondylitis Center

Apr 25th, 2017 - The incidence of inflammatory bowel disease (IBD) has been increasing in Hong Kong. The management of inflammatory bowel disease involved the use of immunosuppressant, however, the use of immunosuppressant in patients with hepatitis B infection ha...

Oct 23rd, 2012 - Tumor necrosis factor α inhibitors (TNF blockers) have revolutionized the treatment of patients with anklyosing spondylitis. Despite clinical efficacy, there are questions and controversies treating rheumatologists face, which this review discusse...

Apr 25th, 2017 - The incidence of inflammatory bowel disease (IBD) has been increasing in Hong Kong. The management of inflammatory bowel disease involved the use of immunosuppressant, however, the use of immunosuppressant in patients with hepatitis B infection ha...

Nov 1st, 2016 - ClinicalTrials.gov has listed the results of the POSTURE study, a large randomized placebo-controlled trial wherein apremilast (Otezla) was found to yield no benefit compared to placebo in treating ankylosing spondylitis (AS) patients (32.5% versu...

Jun 9th, 2016 - LONDON, United Kingdom — The oral Janus kinase (JAK) inhibitor tofacitinib (Xeljanz, Pfizer) might be a new option for patients with ankylosing spondylitis, according to results from a new phase 2 study. "This is the first study to demonstrate the...

Jun 9th, 2016 - LONDON, United Kingdom — The oral Janus kinase (JAK) inhibitor tofacitinib (Xeljanz, Pfizer) might be a new option for patients with ankylosing spondylitis, according to results from a new phase 2 study. "This is the first study to demonstrate the...